3-pyridinecarboxamide, 2-(1-piperazinyl)-: A Chemical Manufacturer’s Perspective

Putting Years of Synthesis Experience to Work

On the plant floor, we see how subtle variations in molecular structure shape a chemical’s role. 3-pyridinecarboxamide, 2-(1-piperazinyl)- brings together the pyridine core and the versatile piperazine ring, connecting two proven chemistries into one adaptable molecule. Its CAS number, 39562-39-5, marks it uniquely in our inventory, but what truly sets it apart is what we have observed in hands-on manufacture and applied research. Over the years, we’ve scaled this compound from lab grams to batch levels for pharmaceutical development and specialty intermediates, learning to recognize its strengths and limitations through practical experience.

This compound frequently enters the process as a linker or building block, providing a foundation for downstream modifications. The structure features a carboxamide group at the 3-position of the pyridine ring, which reacts smoothly under various synthetic conditions. Paired with the 2-(1-piperazinyl) substitution, the molecule lends itself to further derivatization, making it valuable for medicinal chemists investigating new potential leads. Rather than acting as a finished drug, it has proven especially flexible for scaffold design—filling the toolbox for those tackling challenging synthetic targets in pharmaceutical, agrochemical, or dye research.

Specification That Matches Real-World Production

Our standard practice emphasizes reproducibility and clarity. Products leave our reactors as a pale solid, typically off-white to light beige, which reflects the purity we have dialed in over years of optimizations. High-performance liquid chromatography (HPLC) confirms the active content, and we set a limit of not less than 99% by area purity, because trace by-products hurt downstream yields and complicate post-processing. The melting point measures between 168-171°C. This attribute often acts as a quick check for batch identity and integrity during storage and before shipping.

Solubility has become a practical concern for formulators in pharmaceutical R&D. 3-pyridinecarboxamide, 2-(1-piperazinyl)- dissolves in polar aprotic solvents (such as DMF and DMSO), but shows limited solubility in non-polar organic liquids or plain water. During scale-up, we discovered that controlling particle size—down to manageable, flowable powders—helps avoid caking. Flowability matters on real assembly lines, especially for automated feed systems; attention to these practical details reflects years of interaction with formulation partners who report back what works and what clogs hoppers.

Understanding Usage: Not Just a Building Block

Requests for this molecule typically stem from the search for new pharmacophores, where the piperazine motif introduces basicity and the pyridine ring can be tuned for target selectivity. Teams use 3-pyridinecarboxamide, 2-(1-piperazinyl)- as a platform to test a wide array of functionalizations. Our experience shows that the amide linkage holds up well under most conditions—stability testing, both accelerated and long-term, shows the compound resists hydrolytic breakdown in dry storage.

As manufacturers, we have supported projects aiming to introduce this compound into combinatorial chemistry libraries, high-throughput screening panels, and targeted molecular arrays. Some groups pursue analog synthesis by working through the piperazine nitrogen, leveraging its nucleophilicity for alkylation or acylation, while others modify the pyridine ring itself. Each route presents its own synthetic bottlenecks; over the years, we have fine-tuned protocols for monoselectivity and minimized N-oxide by-product formation, directly benefiting customers seeking to maximize yield and purity.

Compared to widely traded pyridine derivatives or more common piperazine-containing molecules, this hybrid structure offers a distinct balance of electronic properties. Experienced chemists tell us that it gives a unique starting point for SAR (structure-activity relationship) studies. The compound doesn’t exhibit the same bulkiness as many benzimidazole or quinoline analogs, yet maintains enough molecular rigidity to support predictable reaction outcomes. For teams running iterative analog syntheses, that predictability shaves weeks off project timelines. Many times, the little details—like fewer chromatographic purification cycles or lower silica usage—make the real-world difference. These are facts observed by those actually weighing, reacting, and scaling the materials, not marketing talking points.

Supply Chain Lessons Learned from Hands-On Distribution

Raw material availability has become as important as synthetic technique. Reliability counts: we work directly with upstream suppliers for essential starting materials such as nicotinic acid, keeping close tabs on every delivery. Downstream, customers tell us that inconsistent suppliers kill momentum in their labs. By managing synthesis internally, we control the timeline and maintain flexibility for special requests, such as custom salt forms or alternate particle size distributions.

Shipping presents challenges, particularly for international customers. Moisture pick-up during long transit can degrade some batches, especially in humid climates, so we have adopted robust packaging. Double-layered polyethylene bags inside steel drums or fiberboard barrels keep the contents safe. These aren’t afterthoughts—shipping issues reported to us from the field become lessons written into our packaging SOPs. Each stage, from synthesis to labeling and export documents, runs under traceable batch records; this transparency supports both regulatory submissions and routine audits.

Difference from Other Products: A Perspective from Production

We produce a range of substituted pyridine and piperazine compounds, providing a sharp perspective on how this molecule stands apart. Many analogs either lack the piperazine group or feature variations at the pyridine’s 2, 3, or 4 position. Those subtle substitutions create tangible differences in reactivity, solubility, and process handling. For example, compounds lacking the 2-(1-piperazinyl) feature often don’t achieve the same breadth of downstream reactivity—especially in activating the amide for further derivatization. Experienced synthetic chemists, both in our own labs and among our customers, report that this difference sometimes spells the line between a stalled project and success in hit expansion.

Another key distinction: Many commercial piperazine derivatives incorporate bulkier or aromatic substituents, increasing lipophilicity but reducing synthetic versatility. These heavier analogs fill important roles, but their purification steps require more complex chromatography, and pricing often reflects increased raw material and processing costs. In contrast, 3-pyridinecarboxamide, 2-(1-piperazinyl)- remains cost-effective across batch scales, largely because its intermediates are familiar and the reaction sequence runs smoothly on existing equipment.

Recent years have shown a rise in demand for so-called “privileged structures” in medicinal chemistry. Our compound fits this trend, yet we’ve learned that not every “privileged” core supports scalable, reproducible processes—the lesson is in the scale-up yields, not abstract claims. After dozens of campaigns, we see that the relatively modest steric profile and stable functional groups of this compound accommodate diverse modifications without introducing batch-to-batch surprises. The time and money saved at kilo scale doesn’t always show up on product flyers, but customers notice the difference over long development cycles.

Regulatory and Documentation Support—Built on Front-Line Familiarity

Working with real projects means facing regulatory expectations every day. As manufacturers, we understand the paperwork burden that can swamp R&D teams. All our documentation begins with accurate, in-house produced Certificates of Analysis and extends to Drug Master File (DMF) support. Material traceability covers not just synthesis but also environmental and worker safety audits. Document queries don’t get handed to a third party—they route directly to people with hands-on knowledge of the compound’s production profile.

We recognize shifting international standards, from ICH guidelines to evolving REACH requirements. Our team prepares full residual solvent listings, impurity profiles, and stability reports—critical for advanced pharmaceutical investigation. Regulatory authorities, especially during site audits, care about cross-contamination prevention and validated cleaning protocols. Because we operate the production lines, not just warehousing, documentation always matches process reality rather than advertising goals.

Batch-to-Batch Consistency: Lessons from the Floor

Customers tell us that off-specification batches cost time and money. Consistency in this molecule has come from years of iterative process improvement: reduced trace metals from catalyst recovery, fewer particulate contaminants, and minimized residual moisture. Experienced packaging staff observe every shipment; we don’t delegate lot testing or visual inspections to outsiders. By handling each process step ourselves, we catch potential problems before the drums ever leave our facility.

Over time, we discovered that even simple process variables—mixing speed, reaction charging sequence, cooling rate—can affect physical attributes. Process knowhow comes from cumulative experience, not checklists. On more than one occasion, operators identified subtle changes in particle size or compressibility that pointed to emerging batch stability issues. Acting early, we refined fine points in crystallization procedures, making sure that each container matches the next.

Collaboration from Both Sides of the Bench

Teams reach out for more than just material; collaboration runs on shared technical understanding. We have worked with researchers troubleshooting reaction conditions, refining scale-up, or validating new analytical methods. In recent years, users in custom API manufacturing and academic labs alike have benefited from straightforward feedback channels. Customers regularly invite us to join early-phase teleconferences or project reviews—those conversations lead to process improvements and sometimes spark ideas for new derivatives.

Understanding this compound’s behavior under pressure filtration, for example, came through combined field testing. A pharmaceutical team encountered filter fouling at scale; drawing on our experience, we recommended a slight solvent polarity shift and a temperature ramp, producing clear filtrates and reducing loss. Joint problem-solving is not just an add-on service; it's part of the value we bring as a manufacturer engaged with chemistry at every scale.

Focus on Environmental Responsibility

Production of complex heterocycles has potential for waste generation. Our investments in closed-loop solvent recovery and byproduct minimization reflect lessons learned from long-running operations. We treat effluent streams in-house, using monitored pH and COD targets. Raw solvent reuses, catalyst recovery, and recirculation of wash liquors are not mere compliance gestures—they preserve bottom-line performance while respecting environmental stewardship. No credible manufacturer remains untouched by increasing regulatory scrutiny around waste minimization, and we welcome site visits or process reviews from downstream partners.

Energy efficiency emerges as another practical focus. Kiln drying, filtration, and crystallization are energy-intensive; integrating multi-effect evaporators and heat exchangers has trimmed process time and costs. By directly measuring our resource usage, we hit sustainability benchmarks that marketing claims can’t substitute. The drive to conserve resources grew not from external pressure, but from experience watching energy spikes erode cost competitiveness over time.

Customer Challenges and Real Solutions

Researchers tackling fast-paced lead optimization need rapid material turnaround and clear technical advice. Sourcing 3-pyridinecarboxamide, 2-(1-piperazinyl)- from our facilities streamlines project planning, as both chemical and logistical know-how reside together. Fast response to specification tweaks, repackaging for pilot reactors, or alternative solvent drying minimizes downtime.

Some customers require micronized forms for direct formulation, while others need extra-large batches for process validation. Being able to adjust workflow on the fly reduces their need for secondary processing, cutting both cost and lead time. Over several years, direct feedback from formulators influenced our internal processes—improving crusher and sieve maintenance schedules, and fine-tuning quality checkpoints in final packaging. These aren’t generic claims; each change corresponds to traceable improvement in product consistency or ease of use reported by end users.

Occasionally, a customer’s synthetic application exposes trace impurities or handling quirks missed by standard QC tests. Honest reporting and iterative process changes follow, not denial or pre-packaged explanations. This difference sets manufacturers apart from resellers—knowledge comes through owning each step, responding directly to practical production and usage experiences.

Continuous Improvement, Not Commodity Thinking

Over time, 3-pyridinecarboxamide, 2-(1-piperazinyl)- has moved from specialty request to established catalog item, but we never approach its manufacture as a commodity. Markets shift, client requirements change, and new regulatory filings emerge. Upgrades in filtration, waste neutralization, and analytical monitoring derive directly from living through production cycles, not from abstract specifications. Continuous improvement shows up in the small details, such as better visual inspections, more precise dissolution tests, and updated shelf-life screens—each based on issues observed in past shipments.

We have seen that direct contact with end users fosters a more responsive way of business. Every challenge returns to the shop floor, inspiring new checks or workflow changes—sometimes as minor as relabeling drums or as major as switching out aging reactor hardware. Investment in these processes makes every future batch more predictable, reliable, and better suited to the sophisticated applications researchers bring. This, in turn, strengthens trust and builds long-term relationships rooted in the realities of production, not just sales volume.

Concluding Thoughts from the Plant

Working with 3-pyridinecarboxamide, 2-(1-piperazinyl)- has given us more than a line on a specification sheet. Our understanding builds on the interplay of synthesis, purification, documentation, packaging, and user interaction. Real knowledge emerges through countless production runs and fielding technical requests from researchers tackling new challenges around the globe. The molecule’s straightforward reactivity, robust stability, and adaptable profile have shaped its value to innovators, but its track record speaks loudest in efficient, reproducible, safe manufacture. Each batch sent out reflects lived experience—both the successes and the problems solved along the way. In chemical manufacturing, those lessons last much longer than any catalog listing.